Dr. Ilan Schwartz said findings from a large-scale study on the efficacy of remdesivir for treating COVID-19 show "there is certainly no mortality benefit.”
Dr. Sebastian Straube comments on research he was involved in that concluded sufficient evidence exists to classify at least 19 procedure groups as aerosol-generating.
